CACNA1D and Parkinson disease: Studies have suggested that certain L-type Ca2+-channel inhibitors used in patients with hypertension to some extent reduce the risk of PD, but currently no FDA approved drugs available to selectively target Cav1.3 in humans (Chan et al., 2009).